S-1 in the treatment of pancreatic cancer

Table 2 Phase II studies of Gemcitabine and S-1 therapy for advanced pancreatic cancer

Ref.	n	Disease extent	ORR	PFS/TTP(mo)	MST(mo)
Nakamura et al[19]	33	Metastatic	48%	5.4	12.5
Ueno et al[20]	54	Metastatic	44.4%	5.9	10.1
Oh et al[21]	38	Metastatic or LA	32%	5.4	8.4
Lee et al[22]	32	Metastatic or LA	44%	4.92	7.89
Kim et al[23]	22	Metastatic or LA	27.3%	4.6	8.5

PFS: Progression-free survival; TTP: Time to progression; MST: Median survival time; LA: Locally advanced; ORR: Objective response rate.